Cellectis SA (CLLS) Expected to Post Earnings of -$0.67 Per Share

Analysts expect Cellectis SA (NASDAQ:CLLS) to report ($0.67) earnings per share for the current quarter, Zacks reports. Four analysts have provided estimates for Cellectis’ earnings, with the highest EPS estimate coming in at ($0.53) and the lowest estimate coming in at ($0.77). Cellectis reported earnings per share of ($0.39) in the same quarter last year, which suggests a negative year over year growth rate of 71.8%. The business is scheduled to issue its next quarterly earnings report on Monday, May 6th.

On average, analysts expect that Cellectis will report full year earnings of ($2.90) per share for the current financial year, with EPS estimates ranging from ($3.55) to ($2.14). For the next financial year, analysts forecast that the company will report earnings of ($2.11) per share, with EPS estimates ranging from ($2.82) to ($1.42). Zacks’ EPS calculations are an average based on a survey of research firms that follow Cellectis.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.14. Cellectis had a negative net margin of 362.48% and a negative return on equity of 18.63%. The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $7.46 million.

Several research analysts have issued reports on CLLS shares. Barclays restated a “buy” rating and set a $50.00 price target on shares of Cellectis in a report on Wednesday, March 13th. Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Thursday, January 3rd. ValuEngine upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a report on Monday. BidaskClub upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a research note on Saturday, March 16th. Finally, Citigroup lowered their price objective on shares of Cellectis from $37.00 to $22.00 and set a “neutral” rating for the company in a research note on Monday, March 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $32.00.

Cellectis stock opened at $19.58 on Monday. Cellectis has a 52-week low of $15.34 and a 52-week high of $35.08.

Large investors have recently added to or reduced their stakes in the company. Financial Gravity Companies Inc. bought a new stake in shares of Cellectis in the 4th quarter valued at $71,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Cellectis by 37.6% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,545 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 1,787 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Cellectis in the 4th quarter valued at $180,000. KBC Group NV increased its stake in shares of Cellectis by 22.9% in the 4th quarter. KBC Group NV now owns 14,266 shares of the biotechnology company’s stock valued at $238,000 after acquiring an additional 2,661 shares in the last quarter. Finally, Squarepoint Ops LLC increased its stake in shares of Cellectis by 28.3% in the 4th quarter. Squarepoint Ops LLC now owns 16,455 shares of the biotechnology company’s stock valued at $274,000 after acquiring an additional 3,626 shares in the last quarter. Institutional investors own 27.61% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).

Featured Story: What is Blockchain?

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.